Dry powder inhalation as a potential delivery method for vaccines

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1796-1803

  Licalsi, Cynthia ^a   Christensen, Troy ^a   Bennett, John V ^b   Phillips, Elaine ^a   Witham, Clyde ^a  

^a Dura Pharmaceuticals   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Aerosols; Dry powder inhalation; Measles vaccine

Indexed keywords

MEASLES VACCINE;

AEROSOL; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; HUMAN; INFANT; INHALATION; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THERMOSTABILITY;

ADMINISTRATION, INHALATION; AEROSOLS; HUMANS; MEASLES VACCINE; POWDERS;

EID: 0344141391     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00438-1     Document Type: Conference Paper

References (33)

1. Ogra P.L., Fishaut M., Gallagher M.R. Viral vaccination via the mucosal routes. Rev. Infect. Dis. 2:1980;352-369.
2. Czerkinsky C., Holmgren J. The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccines. Immunologist. 3:1995;97-102.
3. Pedersen I.R., Mordhorst C.H., Glikmann G., von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine. 7:1989;345-348.
4. Patton J.S., Trichero P., Platz R.M. Bioavailability of pulmonary delivered peptides and proteins: alpha-Interferon, calcitonins and parathyroid hormones. J. Control. Release. 28:1994;79-85.
5. Wall D.A. Pulmonary absorption of peptides and proteins. Drug Deliv. 2:1995;1-20.
6. Byron P.R., Aerosol formulation, generation and delivery using nonmetered systems. In: Byron P.R., editor. Respiratory drug delivery. Boca Raton: CRC Press, Inc., 1990. p. 143-65.
7. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 75:1993;295-305.
8. Russell S.M., Sparrow R.L., McKenzie I.F., Purcell D.F. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur. J. Immunol. 22:1992;1513-1518.
9. Sabin A.B. Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br. Med. J. (Clin. Res. Ed.). 292:1986;531-533.
10. Sabin A.B., Fernandez de Castro J., Flores Arechiga A., Sever J.L., Madden D.L., Shekarchi I. Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet. 2:1982;604. [letter].
11. Sabin A.B., Flores Arechiga A., Fernandez de Castro J., Sever J.L., Madden D.L., Shekarchi I., Albrecht P. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA. 249:1983;2651-2662.
12. Sabin A.B., Flores Arechiga A., Fernandez de Castro J., Albrecht P., Sever J.L., Shekarchi I. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA. 251:1984;2363-2371.
13. Fernandez de Castro J., Valdespino Gomez J.L., Diaz Ortega J.L., Zarate Aquino M.L. Diploid cell measles vaccine. JAMA. 256:1986;714. [letter] [published erratum appears in JAMA 1986 October 24-31;256(16):2200].
14. Fernandez de Castro J., Kumate J. La vacunacion contra el sarampion: situacion en Mexico e America: avances en el meodo de immunizacion por aerosol. Bol. Med. Hosp. Infant. Mex. 47:1990;449-461.
15. Sabin A.B. Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur. J. Epidemiol. 7:1991;1-22.
16. Kane A., Kane M., Lloyd J., Zaffran M. Unsafe injections in the developing world and transmission of blood-borne pathogens: review of the literature and regional estimates. 1998 Expanded Program on Immunization (WHO/EPI/TECHNET.98/BK11).
17. UNICEF. State of the world's children 1998. Oxford and New York: Oxford University Press, 1998. p. 97, 105.
18. WHO, UNICEF. State of the world's vaccines and immunization. Geneva, Switzerland, WHO/GPV/96.04, 1996. p. 159.
19. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals. 25:1997;323-338.
20. Kress S., Schluederberg A.E., Hornick R., Morse L.J., Cole J.L., Slater E.A., McCrumb F.R. Studies with live attenuated measles-virus vaccine. Am. J. Dis. Child. 101:1961;57-63.
21. Okuno Y. Vaccination with egg passage measles virus by inhalation. Am. J. Dis. Child. 103:1962;211-214.
22. McCrumb F. Studies with live attenuated measles virus vaccine: clinical and immunologic responses in institutionalized children. Am. J. Dis. Child. 101:1961;45-56.
23. McCrumb F., Bulkeley J., Hornick R., Snyder M., Togo Y. Clinical trials with living attenuated measles virus vaccines. Am. J. Public Health. 52:1962;11-15.
24. Terskikh A., Danilov A., Sheltchkov G., Fadeeva L., Khaletskaya E. Theoretical substantiation and effectiveness of immunization with aerosols of liquid measles vaccine. Vesta. Akad. Med. Narek. 26:1971;84-90.
25. Okuno Y., Ueda S., Hosai H., Kitawaki T., Nakamura K., Chiang T., Okabe S., Onaka M. Studies on the combined use of killed and live measles vaccines II. Advantages of the inhalation method. Biken J. 8:1965;81-85.
26. Ueda S., Hosai H., Minekawa Y., Okuno Y. Studies on the combined use of killed and live measles vaccine. III. Conditions for the 'take' of live vaccine. Biken J. 9:1966;97-101.
27. Danilov A., The basis for vaccination against measles by aerosols of live vaccine. In: Hers J.F.P., Winkler K.C., editors. Airborne transmission and airborne infection. New York: John Wiley and Sons, 1973. p. 344-5.
28. Cutts F.T., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals. 23:1995;95-106.
29. Fernandez de Castro J., Kumate J., Sepulveda J., Ramirez J., Valdespino J. La vacunacion antisarampionosa en Mexico por el metodo de aerosol. Solud. Publica. Mex. 39:1997;53-60.
30. Melnick J.L. Thermostability of poliovirus and measles vaccines. Dev. Biol. Stand. 87:1996;155-160.
31. Phillips E., Allsopp E., Christensen T., Fitzgerald M., Zhao L. Size reduction of peptides and proteins by jet-milling. In: Dalby R.N., Byron P.R., Farr S.J., editors. Respiratory drug delivery, vol. VI. Buffalo Grove: Interpharm Press, Inc., 1998. p. 161-8.
32. Hill M., Vaughan L., Dolovich M. Dose targeting for dry powder inhalers. In: Dalby R.N., Byron P.R., Farr S.J., editors. Respiratory drug delivery, vol. V. Buffalo Grove: Interpharm Press, Inc., 1996. p. 197-208.
33. Williams D.R., Mecikalski M.B., Thueson D.O. Apparatus for aerosolizing powdered medicine and process and using. US patent document. USA: Dura Pharmaceuticals Inc., San Diego, CA, 1994.